BMS’s Zeposia (ozanimod) Receives the CHMP’s Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease

 BMS’s Zeposia (ozanimod) Receives the CHMP’s Positive Opinion to Treat Adults with Relapsing-Remitting Multiple Sclerosis with Active Disease

BMS Reports Results of Triple Regimen in P-III ELOQUENT-1 Study for Patients with Newly Diagnosed Untreated Multiple Myeloma

Shots:

  • The approval is based on P-III SUNBEAM & RADIANCE Part B studies assessing Zeposia (0.92 mg and 0.46 mg, equivalent to 1 mg and 0.5 mg ozanimod HCI) vs Avonex (qw, IM) in 1,346 & 1,320 patients with RMS for at least 12 & 24mos. treatment period respectively
  • The results will further be reviewed by the European Commission, which has the authority to approve medicines for the European Union
  • Zeposia (ozanimod) is an oral S1P receptor modulator involved in binding with S1P receptors 1 and 5. On Mar 25, 2020 the US FDA approved Zeposia for the treatment of adults with relapsing forms of multiple sclerosis (RMS)

Click here ­to­ read full press release/ article | Ref: BMS | Image: BMS

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post